{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:39Z","timestamp":1791559419439,"version":"4.3.4"},"reference-count":26,"publisher":"American Veterinary Medical Association (AVMA)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To evaluate the effectiveness of canine parvovirus monoclonal antibody (CPMA) as a treatment against canine parvovirus (CPV-2)\u2013induced mortality and to support USDA product licensure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>28 purpose-bred Beagle dogs aged 8 weeks were randomized to the treated (n = 21) or control (7) group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Dogs were challenged intranasally with 10<jats:sup>4.2<\/jats:sup> TCID<jats:sub>50<\/jats:sub> virulent CPV-2b on Day 0 and monitored for 14 days for fecal viral shed and clinical disease. All dogs began shedding CPV-2 on Day 4 and were treated intravenously with a single dose of either CPMA (0.2 mL\/kg) or saline (equal volume). No additional treatments were given to either group. Feces and sera were collected for quantitative analysis of fecal viral shed (hemagglutination) and antibody responses (hemagglutination inhibition and dot-blot ELISA), respectively. Dogs were monitored twice daily for parameters including lymphopenia, fever, vomiting, abnormal feces, inappetence, and lethargy. Humane endpoints triggered euthanasia by a veterinarian masked to treatment groups. The primary outcome variable was prevention of mortality as compared to controls.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Mortality was prevented in all CPMA-treated dogs compared to 57% mortality in the control group (<jats:italic>P<\/jats:italic> = .0017, Fisher exact test). Canine parvovirus monoclonal antibody\u2013treated dogs also experienced less severe and\/or shorter durations of diarrhea, fever, vomiting, CPV-2 shedding in feces, and lymphopenia. Both groups showed similar immunoglobulin M responses as measured by semiquantitative analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Intravenous administration of CPMA can effectively improve clinical outcome when administered early in CPV-2 disease. Canine parvovirus monoclonal antibody treatment after proven infection does not interfere with adaptive immunity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.23.09.0541","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T14:05:25Z","timestamp":1706709925000},"page":"506-512","source":"Crossref","is-referenced-by-count":15,"title":["Early administration of canine parvovirus monoclonal antibody prevented mortality after experimental challenge"],"prefix":"10.2460","volume":"262","author":[{"given":"Laurie","family":"Larson","sequence":"first","affiliation":[{"name":"School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Miller","sequence":"additional","affiliation":[{"name":"LFM Quality Laboratories Inc, Terre Haute, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Margiasso","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Piontkowski","sequence":"additional","affiliation":[{"name":"Bighorn Veterinary Consulting, Perry, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dykstra","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miller","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton J.","family":"Slagter","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Champ","sequence":"additional","affiliation":[{"name":"DAC Consulting, Ames, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Keil","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Patel","sequence":"additional","affiliation":[{"name":"Elanco Animal Health, Greenfield, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Wasmoen","sequence":"additional","affiliation":[{"name":"Innovative Biotech Consulting, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"3","key":"ref1","series-title":"Vet Clin North Am Small Anim Pract","first-page":"555","article-title":"Canine parvovirus","volume":"23","author":"Pollock RV","year":"1993","unstructured":"Pollock RV, Coyne MJ. Canine parvovirus. Vet Clin North Am Small Anim Pract. 1993;23(3):555-568. doi:10.1016\/s0195-5616(93)50305-4"},{"issue":"1","key":"ref2","series-title":"J Am Vet Med Assoc","first-page":"37","article-title":"Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination","volume":"180","author":"Pollock RVH","year":"1982","unstructured":"Pollock RVH, Carmichael LE. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc. 1982;180(1):37-42."},{"issue":"4","key":"ref3","series-title":"Comp Immunol Microbiol Infect Dis","first-page":"281","article-title":"Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine","volume":"15","author":"Buonavoglia C","year":"1992","unstructured":"Buonavoglia C, Tollis M, Buonavoglia D, Puccini A. Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine. Comp Immunol Microbiol Infect Dis. 1992;15(4):281-283. doi:10.1016\/0147-9571(92)90007-e"},{"issue":"3","key":"ref4","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"167","article-title":"Canine parvoviral enteritis: a review of diagnosis, management, and prevention","volume":"14","author":"Prittie J","year":"2004","unstructured":"Prittie J. Canine parvoviral enteritis: a review of diagnosis, management, and prevention. J Vet Emerg Crit Care (San Antonio). 2004;14(3):167-176. doi:10.1111\/j.1534-6935.2004.04020.x"},{"key":"ref5","article-title":"US patent application No. 17\/630,685","author":"Zhan H","year":"2022","unstructured":"Zhan H, Nguyen L, Ratcliff E, Chin R, Li S. US patent application No. 17\/630,685. 2022."},{"key":"ref6","article-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council of the National Academies Press","year":"2011","unstructured":"National Research Council of the National Academies Press. Guide for the Care and Use of Laboratory Animals. 8th ed. National Academy of Sciences; 2011."},{"key":"ref7","series-title":"Waltham Petcare Science Institute","article-title":"The Waltham faeces scoring system","author":"Moxham G","unstructured":"Moxham G. The Waltham faeces scoring system. Waltham Petcare Science Institute. Accessed November 7, 2022. https:\/\/www.waltham.com\/news-events\/nutrition\/why-monitor-your-dogs-faeces"},{"issue":"5","key":"ref8","series-title":"Am J Vet Res","first-page":"784","article-title":"Hemagglutination by canine parvovirus: serologic studies and diagnostic applications","volume":"41","author":"Carmichael LE","year":"1980","unstructured":"Carmichael LE, Joubert JC, Pollock RV. Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res. 1980;41(5):784-791."},{"key":"ref9","article-title":"Prevented Fraction Methods","author":"Siev D","year":"2012","unstructured":"Siev D, Tong C. Prevented Fraction Methods. USDA Center for Veterinary Biologics; 2012. Document STATWI0007.01. Accessed September 26, 2023. https:\/\/www.aphis.gov\/animalhealth\/vetbiologics\/publications\/STATWI0007.pdf"},{"issue":"4","key":"ref10","series-title":"Vet Ther","first-page":"305","article-title":"Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine","volume":"8","author":"Larson LJ","year":"2007","unstructured":"Larson LJ, Schultz RD. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Vet Ther. 2007;8(4):305-310."},{"issue":"2","key":"ref11","series-title":"Vet Ther","first-page":"94","article-title":"Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?","volume":"9","author":"Larson LJ","year":"2008","unstructured":"Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94-101."},{"issue":"1-2","key":"ref12","series-title":"Vet Microbiol","first-page":"1","article-title":"Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies? A systematic review of controlled clinical trials","volume":"180","author":"Hern\u00e1ndez-Blanco B","year":"2015","unstructured":"Hern\u00e1ndez-Blanco B, Catala-L\u00f3pez F. Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies? A systematic review of controlled clinical trials. Vet Microbiol. 2015;180(1-2):1-9. doi:10.1016\/j.vetmic.2015.07.027"},{"key":"ref13","series-title":"J Nutr Sci","first-page":"e54","article-title":"Protection against canine parvovirus type 2 infection in puppies by colostrum-derived antibodies","volume":"3","author":"Mila H","year":"2014","unstructured":"Mila H, Grellet A, Desario C,  Protection against canine parvovirus type 2 infection in puppies by colostrum-derived antibodies. J Nutr Sci. 2014;3:e54. doi:10.1017\/jns.2014.57"},{"issue":"24","key":"ref14","series-title":"Vet Rec","first-page":"573","article-title":"Canine parvovirus: interaction between passive immunity and virulent challenge","volume":"122","author":"Macartney L","year":"1988","unstructured":"Macartney L, Thompson H, McCandlish IA, Cornwell HJ. Canine parvovirus: interaction between passive immunity and virulent challenge. Vet Rec. 1988;122(24):573-576. doi:10.1136\/vr.122.24.573"},{"issue":"1","key":"ref15","series-title":"Vet Microbiol","first-page":"75","article-title":"Duration of immunity for canine and feline vaccines: a review","volume":"117","author":"Schultz RD","year":"2006","unstructured":"Schultz RD. Duration of immunity for canine and feline vaccines: a review. Vet Microbiol. 2006;117(1):75-79. doi:10.1016\/j.vetmic.2006.04.013"},{"issue":"suppl 1","key":"ref16","series-title":"J Comp Pathol","first-page":"S102","article-title":"Age and long-term protective immunity in dogs and cats","volume":"142","author":"Schultz RD","year":"2010","unstructured":"Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142(suppl 1):S102-S108. doi:10.1016\/j.jcpa.2009.10.009"},{"issue":"2","key":"ref17","series-title":"Benha Vet Med J","first-page":"34","article-title":"Efficacy of canine parvovirus hyperimmune serum prepared in horses for treatment of canine parvo and feline panleucopenia infections","volume":"28","author":"Attyat M","year":"2015","unstructured":"Attyat M, Wafaa RAA. Efficacy of canine parvovirus hyperimmune serum prepared in horses for treatment of canine parvo and feline panleucopenia infections. Benha Vet Med J. 2015;28(2):34-39. doi:10.21608\/bvmj.2015.31858"},{"issue":"5","key":"ref18","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"525","article-title":"Clinical evaluation of hyperimmune plasma for treatment of dogs with naturally occurring parvoviral enteritis","volume":"30","author":"Acciacca RA","year":"2020","unstructured":"Acciacca RA, Sullivan LA, Webb TL, Johnson V, Dow SW. Clinical evaluation of hyperimmune plasma for treatment of dogs with naturally occurring parvoviral enteritis. J Vet Emerg Crit Care (San Antonio). 2020;30(5):525-533. doi:10.1111\/vec.12987"},{"issue":"2","key":"ref19","series-title":"Virology","first-page":"283","article-title":"Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies","volume":"361","author":"Nelson CD","year":"2007","unstructured":"Nelson CD, Palermo LM, Hafenstein SL, Parrish CR. Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology. 2007;361(2):283-293. doi:10.1016\/j.virol.2006.11.032"},{"key":"ref20","series-title":"Curr Top Microbiol Immunol","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/82_2010_33","article-title":"Structures and functions of parvovirus capsids and the process of cell infection","volume":"343","author":"Parrish CR","year":"2010","unstructured":"Parrish CR. Structures and functions of parvovirus capsids and the process of cell infection. Curr Top Microbiol Immunol. 2010;343:149-176. doi:10.1007\/82_2010_33"},{"key":"ref21","article-title":"USDA Center for Veterinary Biologics","author":"196-341520 product compilation summary","unstructured":"196-341520 product compilation summary. USDA Center for Veterinary Biologics. Updated May 23, 2023. Accessed August 21, 2023. https:\/\/www.aphis.usda.gov\/aphis\/ourfocus\/animalhealth\/veterinary-biologics\/product-summaries\/vet-label-data\/bd2b6b5d-cfde-40bf-9ecb-e8fd5a525050"},{"key":"ref22","series-title":"Isr J Vet Med","first-page":"12","article-title":"Diagnosis of acute canine parvovirus infection (CPV-2) in naturally infected dogs using serum IgM and IgG rapid dot ELISA","volume":"59","author":"Waner T","year":"2004","unstructured":"Waner T, Keren-Kornblatt E, Shemesh O, Mazar S. Diagnosis of acute canine parvovirus infection (CPV-2) in naturally infected dogs using serum IgM and IgG rapid dot ELISA. Isr J Vet Med. 2004;59:12-15."},{"issue":"18","key":"ref23","series-title":"Mol Immunol","first-page":"1141","article-title":"Role of natural and immune IgM antibodies in immune responses","volume":"37","author":"Boes M","year":"2000","unstructured":"Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol. 2000;37(18):1141-1149. doi:10.1016\/S0161-5890(01)00025-6"},{"key":"ref24","series-title":"Greene\u2019s Infectious Diseases of the Dog and Cat","first-page":"341","article-title":"Canine parvovirus infections and other viral enteritides","author":"Parrish CR","year":"2023","unstructured":"Parrish CR, Sykes JE. Canine parvovirus infections and other viral enteritides. In: Sykes JE, ed. Greene\u2019s Infectious Diseases of the Dog and Cat. 5th ed. Elsevier; 2023:341-351."},{"issue":"12","key":"ref25","series-title":"Aust Vet J","first-page":"468","article-title":"Duration of serological response to canine parvovirus-type, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia","volume":"90","author":"Mitchell RJ","year":"2012","unstructured":"Mitchell RJ, Zwiinenberg J, Huang J, Day MJ. Duration of serological response to canine parvovirus-type, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia. Aust Vet J. 2012;90(12):468-73. doi:10.1111\/j.1751-0813.2012.01009.x"},{"issue":"1","key":"ref26","series-title":"AMB Express","first-page":"76","article-title":"A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2","volume":"12","author":"Zhou L","year":"2022","unstructured":"Zhou L, Wu H, Du M,  A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2. AMB Express. 2022;12(1):76. doi:10.1186\/s13568-022-01416-8"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/4\/javma.23.09.0541.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/4\/javma.23.09.0541.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/4\/javma.23.09.0541.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:51:43Z","timestamp":1727301103000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/4\/javma.23.09.0541.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":26,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.2460\/javma.23.09.0541","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}